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Abstract To elucidate the regulation mechanism of adrenomeduilin 
(AM) production in blood vessels, we examined the effects of 30 
substances on AM production in cultured rat vascular smooth 
muscle cells (VSMCs). Forskolin and 8-bromo-cAMP sup- 
pressed production and gene transcription of AM. Since VSMC 
expresses AM receptors coupled with adenylate cyclase, AM 
production may be regulated by intracellular cAMP concentra- 
tion. Thrombin, vasoactive intestinal polypeptide and interferon- 
also inhibited AM production, while angiotensin II, endothelin- 
1, bradykinin, substance P, adrenaline, phorbol ester and fetal 
calf serum stimulated AM production in VSMC. These results 
suggest that AM production is regulated by a variety of sub- 
stances, indicating complex systems regulating AM production. 
Key words. Adrenomedull in;  cAMP:  Vasoactive peptide; 
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!. Introduction 
Vascular tone is regulated by many factors coming from the 
blood stream, endothelial cells (ECs) and perivascular nerves 
[I 3]. Recent studies have verified that VSMCs are also active 
sources of bioactive substances, such as interleukin-1 (IL-1) 
and endothelin-1 (ET-1), which in turn act on VSMCs, ECs and 
other surrounding cells and regulate their function [4,5]. 
AM is a potent vasorelaxant peptide recently isolated from 
pheochromocytoma tissue [6,7]. We have demonstrated that 
AM is produced in VSMC and that AM mRNA level in VSMC 
is about 4 times higher than that in AM-producing tissue, such 
as adrenal gland [8]. Furthermore,  AM specific receptors cou- 
pled with adenylate cyclase have been shown to be expressed 
on VSMC [9,10]. These data suggest hat AM functions as an 
autocrine or paracrine factor regulating vascular tone. We have 
recently reported that AM product ion in VSMC is highly aug- 
mented by tumor necrosis factor (TNF), IL-I and lipopolysac- 
charide (LPS) [11]. However, there should be more substances 
regulating AM production, since VSMC are known to be regu- 
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Abbreviations." AM. adrenomedullin; EC, endothelial cell; VSMC, vas- 
cular smooth muscle cell; ET, endothelin; it, immunoreactive; R1A, 
radioimmunoassay: DMEM, Dulbeceo's Modified Eagle Medium: 
ED~0, half-maximal effective dose; 1L, interleukin; TNF, tumor necro- 
sis factor: LPS. lipopolysaccharide; AVE arginine vasopressin; Ang I1, 
angiotensin It; CGRP, calcitonin gene-related peptide; INF, interferon; 
ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, 
C-type natriuretic peptide; PGI2, prostaglandin I2; PAF, platelet acti- 
vating factor; VII ), vasoactive intestinal polypeptide; FCS, fetal calf 
serum; TPA, 12-O-tetradecanoylphorbol-13-acetate; 8-Br-cAMP, 8- 
bromo-cAMP: 8-Br-cGMP, 8-bromo-cGMP; iNOS, inducible NO syn- 
thase. 
lated by many vasoactive substances. Thus, we systematically 
applied 30 substances to cultured rat VSMC and measured the 
AM product ion levels. 
2. Materials and methods 
2.1. Materkds 
The following materials were used: murine interferon-:z (IN F-c0 and 
INF-,8 (Calbiochem); rat INF- 7 and fetal calf serum (FCS) (Gibco); 
adrenaline, thrombin, 8-bromo-cAMP (8-Br-cAMP) and 8-bromo- 
cGMP (8-Br-cGMP) (Sigma); noradrenaline, carbachol, serotonin, his- 
tamine, prostaglandin I2 (PG12), adenosine, 12-O-tetradecanoyl phor- 
bol-I 3-acetate (TPA) and forskolin (Wako Pure Chemicals): dopamine 
(Nakarai Tesque); platelet activating factor C16 (PAF C16) (Cascade 
Biochem). Human AM[40 52]-NH2 and its N-Tyr derivative were syn- 
thesized by a peptide synthesizer (Applied Biosystems, 431A). All other 
peptides were of rat origin and were purchased from Peptide Institute. 
TPA, PGI2 and forskolin were first dissolved in ethanol and diluted 
with an incubation medium (Dulbecco's Modified Eagle Medium 
(DMEM) containing 0.1% bovine serum albumin}. 
2.2. Cell culture 
VSMC-1 and VSMC-2 were prepared from Sprague Dawley rat 
thoracic aorta by the explant method and VSMC-3 by the enzyme 
dispersion method [8,11]. VSMC-2 was kindly donated from Dr. M. 
Furuya (Suntory Institute for Biomedical Research) [12]. VSMC-I was 
used for all AM production assays except for those in Fig. 3. VSMC 
was maintained in DMEM containing 10% FCS at 37°(7 in a humidi- 
fied atmosphere containing 5% CO: and was used at passages 8 20. 
2.3. Preparation o['conditioned medium 
VSMCs, grown to confluence in 6-well plates, were washed twice 
with DMEM and preincubated in the incubation media (serum-free 
DMEM containing 0.1% bovine serum albumin} for 2 h. The incuba- 
tion media were then replaced with those containing stimulants ( I ml) 
and incubated for 16 or 24 h at 37°C. Conditioned media thus obtained 
were acidified with acetic acid, heated at 100°C t\)r 10 rain and lyophil- 
ized. The media incubated with catecholamines and FCS were treated 
with Sep-Pak C18 cartridges (Millipore, Waters Division) and adsorbed 
materials on the cartridges were eluted with 60% CFLCN in 0.1~ 
trifluoroacetic acid. The eluate was lyophilized, dissolved in a radioim- 
munoassay (RIA) bult"er and submitted to RIA for AM. 
2.4. RIA jor AM 
Details of the RIA system using antiserum #172CI-7 against human 
AM[40 52]-NH:, which recognizes the C-terminal amide structure 
common to human and rat AMs. have been reported [13]. 
2.5. RNA hlol analysis 
RNA blot analysis for AM was perlbrmed as reported [14]. Total 
RNA (25 ,ug) was electrophoresed and transferred tonylon membrane. 
EeoRI-BglI fragment of rat AM eDNA (nucleotide 153-422) was used 
as a probe [15]. The membrane was re-hybridized to rat glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH) eDNA probe. Band intensity 
was estimated by a Bioimage analyser (Fuji Film, BAS 2000) and was 
compared after correction with GAPDH band intensity. 
2.6. Statistics 
Values were expressed as mean + S.E.M. Statistical analysis of data 
was performed by Student's t test and P<0.01 was considered statisti- 
cally significant. 
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3. Resu l ts  
The concentration of immunoreactive (ir-) AM accumulated 
in the incubation medium of VSMC was measured, since AM 
was shown to be produced and constitutively secreted from 
VSMC into the culture medium [8]. As shown in Table 1, 12 
substances significantly influenced AM production in cultured 
rat VSMC. In the three INFs, only INF-  F showed a weak 
inhibitory effect, decreasing ir-AM concentration to 72% of the 
control. Forskolin and thrombin markedly suppressed AM 
production and AM concentration in the medium was de- 
creased to 30 and 33% of the control. These two substances 
were found to be the most potent inhibitors of AM production 
in VSMC. 8-Br-cAMP also lowered ir-AM concentration to 
68% of the control. Among 12 vasoactive peptides examined, 
angiotensin II (Ang II), bradykinin, substance P and ET-1 
increased ir-AM concentration to 156, 1 16, 128 and 123% of 
the control, while only vasoactive intestinal polypeptide (VIP) 
reduced it to 74% of the control. We checked 3 catecholamines, 
but only adrenaline showed 42% increase of i t -AM concentra- 
tion. FCS and TPA stimulated AM production, as described 
below. The other substances listed in Table 1 did not induce any 
significant effects on AM production under the conditions used 
in the present study. 
We examined effects of Ang II, TPA and FCS on AM pro- 
duction in detail. As shown in Fig. I, Ang II dose-dependently 
stimulated AM production with an EDs0 value of about 0.02 
t iM and maximal Jr-AM level was 156% of the control, indicat- 
ing that Ang II was the most potent stimulant among the 
vasoactive peptides examined. TPA and FCS did not dose- 
dependently stimulate AM production. TPA increased Jr-AM con- 
centration to 127% of the control at 10 nM, but decreased it to 
75% at 10/IM. 0.1-1% of FCS maximally stimulated AM produc- 
tion, and higher concentrations of FCS induced weaker effects. 
Effects of forskolin, thrombin, VIP, INF-F and 8-Br-cAMP 
were further examined, as shown in Fig. 2. Forskolin and 
thrombin suppressed AM production in a dose-dependent 
manner with EDs0 values of 0.2-0.5/ IM and 0.02-0.05 N IH 
U/ml and decreased ir-AM concentration in the incubation 
medium to 42 and 43% of the control after 16 h incubation. 
These substances also decreased AM mRNA level to 46 and 
Table 1 
Effects of various timulants on AM production i  cultured rat vascular 
smooth muscle cells 
Stimulants Concentration Jr-Am 
(fmol/105 cells/24 h) 
control 
INF-c~ 
INF-fl 
INF- 7 
Ang II 
AVP 
ANP 
BNP 
CNP 
bradykinin 
substance P 
ET-1 
CGRP 
VIP 
oxytocin 
neuropeptide Y 
adrenaline 
noradrenaline 
dopamine 
carbachol 
serotonin 
PGI2 
histamine 
PAF C~6 
adenosine 
thrombin u 
FCS 
TPA 
forskolin 
8-Br-cAMP 
8-Br-cGMP 
100 units/ml 
100 units/ml 
100 units/ml 
2/~M 
2/tM 
1/ /M 
1 /dM 
1 / /M 
2/,/M 
2,uM 
2/zM 
0.1 uM 
0.1 uM 
0.1 uM 
0.5 uM 
0.1 uM 
0.1 uM 
0.1 uM 
0.1 uM 
10 '~M 
10 uM 
10 ,tM 
1 /IM 
1 ktM 
10 units/ml 
0.1% 
10 nM 
2/~M 
1 mM 
1 mM 
10.37 + 0.30 
11.09 _+ 0.42 
10.67 + 0.87 
7.51 _+ 0.23* 
16.20 _+ 0.56* 
9.87 _+ 0.33 
8.75 + 0.34 
9.63 + 0.44 
9.05 + 0.52 
12.03 + 0.39* 
13.27 _+ 0.99* 
12.79 + 0.25* 
10.98 + 0.98 
7.76 +_ 0.17' 
10.88 _+ 0.71 
9.58 + 0.20 
14.80 + 0.96* 
12.26 + 1.98 
9.63 _+ 0.73 
9.27 + 0.43 
8.21 + 0.45 
9.43 + 0.37 
10.60 _+ 0.43 
9.86 + 0.88 
10.50 _+ 0.28 
3.38 + 0.12" 
14.53 + 0.88* 
13.19 _+ 0.42* 
3.15 + 0.08* 
7.10 + 0.44* 
9.69 _+ 0.45 
Each value represents mean _+ S.E.M. of three or six separate 
*Statistically significant difference from control (P < 0.01). 
UNIH units. 
wells. 
19% of the control. VIP decreased ir-AM concentration i  a 
dose-dependent manner to 72% of the control with an EDm 
value of 1 nM. INF-7 and 8-Br-cAMP were found to induce 
significant inhibitory effects only at 100 U/ml and 1 mM, re- 
spectively (data not shown). 
We have about 10 different rat VSMC cell lines, which show 
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Fig. I. Dose-dependent effect of Ang II, TPA and FCS on AM production in cultured rat VSMC (VSMC-1). Ir-AM concentration in culture medium 
of rat VSMC was measured after 24 h incubation with (a) Ang II, (b) TPA and (c) FCS. Each point represents mean _+ S.E.M. of six separate wells. 
*P < 0.01. 
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Fig. 2. Dose-dependent i hibition of AM production and gene expression in cultured rat VSMC (VSMC-I) by forskolin, thrombin and V1P 
stimulations. (a) Ir-AM concentration i  culture medium after 16 h incubation with forskolin (),/aM), thrombin (e, NIH U/ml) and VIP (,%/aM). 
Each point represents mean + S.E.M. of six separate wells. *P < 0.01. (b) AM mRNA level in rat VSMC incubated with forskolin (:) and thrombin 
(e) for 16 h. (c) RNA blot analysis of AM transcripts in rat VSMC incubated with forskolin (upper panel) and thrombin (lower panel) for 16 h. 
Each lane contains 25/ag of total RNA. 
different morphological features and biochemical properties 
such as cAMP generation. Three of these cell lines were charac- 
terized by stimulating with typical substances (Fig. 3). After 24 
h stimulation, ir-AM concentrations in the medium of VSMC- 
1, VSMC-2 and VSMC-3 were increased to 410, 149 and 552% 
of the control by IL-lf l  (10 ng/ml) and to 471, 358 and 694% 
by TNF-~ (20 ng/ml), while forskolin (2 ~M) decreased ir-AM 
concentration to 30, 31 and 68% of the control. Thrombin (10 
NIH U/ml) decreased ir-AM concentration to 33 and 26% of 
the control in VSMC-1 and VSMC-2, but increased it to 284% 
in VSMC-3. 
4. Discussion 
Among lhe substances examined, forskolin potently inhib- 
ited AM production and gene transcription in cultured rat 
VSMC (Fig. 2). 8-Br-cAMP also suppressed AM production 
to a lesser extent. These results suggest that production and 
gene transcription of AM are down-regulated by an intracellu- 
lar cAMP concentration. AM receptors, coupled with the 
adenylate cyclase system, have been shown to be present on 
VSMC [9,10]. AM is produced and secreted from VSMC and 
the secreted AM then binds AM receptors on VSMC, resulting 
in elevation of intracellular cAMP level. If AM concentration 
is high enough, AM production might be suppressed by a feed- 
back mechanism through cAMR VIP, which increases intracel- 
lular cAMP concentration, also inhibits AM production. These 
results support the presence of a cAMP-mediated inhibitory 
pathway of AM production in VSMC. Although cAMP-regu- 
lated enhancers are present in the 5'-upstream region and in- 
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Fig. 3. Differential responses of AM production to IL-lfl, TNF-m forskolin and thrombin stimulations in three rat VSMC cell lines. Ir-AM 
concentration i  culture medium of (a) VSMC-I, (b) VSMC-2 and (c) VSMC-3 was measured after 24 h incubation. IL-lfl, TNF-m forskolin and 
thrombin were administered at the final concentrations of 10 ng/ml, 20 ng/ml. 2/aM and 10 NIH U/ml. Each value i'epresents mean _+ S.E.M. of 
three or six separate wells. *P < 0.01. 
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trons of human AM gene [16], the present study indicates that 
these enhancers do not directly function in AM production of 
VSMC. 
Thrombin markedly suppressed AM production and gene 
transcription i two of three VSMC cell lines, but stimulated 
it in one cell line (Figs. 2,3). Thrombin is reported to activate 
protein kinase C (PKC) and cAMP-mediated pathway has not 
been recognized as a major intracellular signaling pathway 
[17,18]. Calcitonin gene-related peptide (CGRP), which utilizes 
cAMP as an intracellular signal [19], induced no effect on AM 
production. These data suggest that regulation of AM produc- 
tion and gene transcription may not be simply attributed to the 
cAMP-mediated pathway. 
TPA, an activator of PKC, elicited weak stimulatory effects 
on AM production in a lower concentration and inhibitory 
effects in a higher concentration (Fig. 1). Ang II and ET-1 elicit 
potent vasoconstriction mainly through a PKC-mediated path- 
way. Although these peptides timulated AM production, in- 
crements of AM production were at most 56% that of the 
control. Several AP-1 and AP-2 sites are found in the 5'-up- 
stream region of the human AM gene [16]. However, these data 
indicate that the PKC-mediated pathway is not enough to in- 
duce a potent stimulatory effect. Natriuretic peptides, which 
activate receptor guanylate cyclases on VSMC, and 8-Br- 
cGMP showed no effect, indicating that cGMP does not regu- 
late AM production in VSMC. 
In other substances xamined, FCS, adrenaline, substance P 
and bradykinin stimulated AM production (Table 1). Stimula- 
tory effect of FCS is not potent but is altered in each FCS 
concentration (Fig. 1). The effects of FCS may fluctuate in 
different lots or producers of FCS and may alter effects of 
stimulants. Thus, we employed the serum-free system for the 
experiments. Since only adrenaline induced significant effects 
in the catecholamines, detailed experiments are required for 
analysing the mechanism of catecholamines. AM induction 
mechanism of substance P and bradykinin, which stimulate 
production of nitric oxide in EC, remains unsolved. 
Among the three INFs, only INF-y inhibited AM produc- 
tion in VSMC. Although 13 INF responsive elements are pres- 
ent in the 5'-upstream region and introns of AM gene [16[, AM 
production was not stimulated by INFs, in contrast to inducible 
NO synthase (iNOS) which has the many elements and has its 
gene expression augmented by INF-y [20,21]. In this study, 
cAMP analogs are also shown to induce quite different effects 
on AM and iNOS production in VSMC [22], although both 
AM and iNOS relax VSMC and their gene expressions are 
commonly augmented by IL-1, TNF and LPS [23]. Regulation 
mechanism ofAM gene transcription a d its relationship tothe 
gene structure is the next problem to be elucidated. 
Three representative c ll lines of VSMC uniformly re- 
sponded to IL-lfl, TNF-c~ and forskolin stimulation (Fig. 3), i.e. 
IL-lfl and TNF-c~ stimulated and forskolin suppressed AM 
production regardless of cell shapes and properties. These data 
suggest that IL-1, TNF and intracellular cAMP regulate AM 
production even in the in vivo system. 
In the present study, we verified that various substances 
influencing VSMC functions also regulate AM production in 
VSMC. These substances probably act simultaneously and in 
the same regions of the vascular wall. Therefore, the AM 
production level may be determined after integration of these 
effects, suggesting a complex regulation system of AM produc- 
tion in VSMC. 
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